نتایج جستجو برای: tp53

تعداد نتایج: 8206  

2014
Mitsuaki Hirose Kenji Yamato Shinji Endo Rie Saito Takunori Ueno Sachiko Hirai Hideo Suzuki Masato Abei Yukikazu Natori Ichinosuke Hyodo

MDM2 and MDM4, a structurally related MDM2 homolog, negatively regulates expression and functions of TP53 tumor suppressor gene. To explore the precise expression patterns and function of MDM2 and MDM4 in wild-type (wt) TP53 cancer cells, we analyzed 11 various cancer cell lines with wt TP53. All cell lines exhibited deregulated expression of MDM2 and MDM4, and were divided into two distinct ty...

2016
Gilles Gadea Nikola Arsic Kenneth Fernandes Alexandra Diot Sébastien M Joruiz Samer Abdallah Valerie Meuray Stéphanie Vinot Christelle Anguille Judit Remenyi Marie P Khoury Philip R Quinlan Colin A Purdie Lee B Jordan Frances V Fuller-Pace Marion de Toledo Maïlys Cren Alastair M Thompson Jean-Christophe Bourdon Pierre Roux

TP53 is conventionally thought to prevent cancer formation and progression to metastasis, while mutant TP53 has transforming activities. However, in the clinic, TP53 mutation status does not accurately predict cancer progression. Here we report, based on clinical analysis corroborated with experimental data, that the p53 isoform Δ133p53β promotes cancer cell invasion, regardless of TP53 mutatio...

2014
Nataliya Zhukova Vijay Ramaswamy Marc Remke Dianna C Martin Pedro Castelo-Branco Cindy H Zhang Michael Fraser Ken Tse Raymond Poon David JH Shih Berivan Baskin Peter N Ray Eric Bouffet Peter Dirks Andre O von Bueren Elke Pfaff Andrey Korshunov David TW Jones Paul A Northcott Marcel Kool Trevor J Pugh Scott L Pomeroy Yoon-Jae Cho Torsten Pietsch Marco Gessi Stefan Rutkowski Laszlo Bognár Byung-Kyu Cho Charles G Eberhart Cecile Faure Conter Maryam Fouladi Pim J French Wieslawa A Grajkowska Nalin Gupta Peter Hauser Nada Jabado Alexandre Vasiljevic Shin Jung Seung-Ki Kim Almos Klekner Toshihiro Kumabe Boleslaw Lach Jeffrey R Leonard Linda M Liau Luca Massimi Ian F Pollack Young Shin Ra Joshua B Rubin Erwin G Van Meir Kyu-Chang Wang William A Weiss Karel Zitterbart Robert G Bristow Benjamin Alman Cynthia E Hawkins David Malkin Steven C Clifford Stefan M Pfister Michael D Taylor Uri Tabori

TP53 mutations confer subgroup specific poor survival for children with medulloblastoma. We hypothesized that WNT activation which is associated with improved survival for such children abrogates TP53 related radioresistance and can be used to sensitize TP53 mutant tumors for radiation. We examined the subgroup-specific role of TP53 mutations in a cohort of 314 patients treated with radiation. ...

Journal: :Ukrainian biochemical journal 2014
S V Danilovskyi D O Minchenko O S Moliavko O V Kovalevska L L Karbovskyi O H Minchenko

Endoplasmic reticulum stress and hypoxia are necessary components of malignant tumors growth and suppression of ERN1 (from endoplasmic reticulum to nuclei-1) signalling pathway, which is linked to the apoptosis and cell death processes, significantly decreases proliferative processes. Glioma cells with ERN1 knockdown were used in order to investigate the effect of ERNI blockade on the expressio...

2009
Yedael Y. Waldman Tamir Tuller Roded Sharan Eytan Ruppin

The tumor suppressor gene TP53 is known to be a key regulator in cancer, and more than half of human cancers exhibit mutations in this gene. Recent evidence shows that point mutations in TP53 not only disrupt its function but also possess gain-of-function and dominant-negative effects on wild-type copies, thus making the mutated gene an oncogene. Hence, this brings about the possibility that TP...

Journal: :Gastroenterology 2011
Hyun Goo Woo Xin Wei Wang Anuradha Budhu Yun Hee Kim So Mee Kwon Zhao-You Tang Zongtang Sun Curtis C Harris Snorri S Thorgeirsson

BACKGROUND & AIMS Mutations in TP53, a tumor suppressor gene, are associated with prognosis of many cancers. However, the prognostic values of TP53 mutation sites are not known for patients with hepatocellular carcinoma (HCC) because of heterogeneity in their geographic and etiologic backgrounds. METHODS TP53 mutations were investigated in a total of 409 HCC patients, including Chinese (n = 3...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2005
Stéphane Berghmans Ryan D Murphey Erno Wienholds Donna Neuberg Jeffery L Kutok Christopher D M Fletcher John P Morris Ting Xi Liu Stefan Schulte-Merker John P Kanki Ronald Plasterk Leonard I Zon A Thomas Look

TP53 is the most frequently mutated tumor suppressor gene in human cancer, with nearly 50% of all tumors exhibiting a loss-of-function mutation. To further elucidate the genetic pathways involving TP53 and cancer, we have exploited the zebrafish, a powerful vertebrate model system that is amenable to whole-genome forward-genetic analysis and synthetic-lethal screens. Zebrafish lines harboring m...

2013
Aaron McCoy Cynthia L. Besch-Williford Craig L. Franklin Edward J. Weinstein Xiaoxia Cui

The tumor suppressor TP53 plays a crucial role in cancer biology, and the TP53 gene is the most mutated gene in human cancer. Trp53 knockout mouse models have been widely used in cancer etiology studies and in search for a cure of cancer with some limitations that other model organisms might help overcome. Via pronuclear microinjection of zinc finger nucleases (ZFNs), we created a Tp53 knockout...

2016
Shi Yun Yeo Yoko Itahana Alvin Kunyao Guo Rachel Han Kozue Iwamoto Hung Thanh Nguyen Yi Bao Kai Kleiber Ya Jun Wu Boon Huat Bay Mathijs Voorhoeve Koji Itahana

Genetic alterations which impair the function of the TP53 signaling pathway in TP53 wild-type human tumors remain elusive. To identify new components of this pathway, we performed a screen for genes whose loss-of-function debilitated TP53 signaling and enabled oncogenic transformation of human mammary epithelial cells. We identified transglutaminase 2 (TGM2) as a putative tumor suppressor in th...

2017
Aline Gottlieb Kristina Althoff Laura Grunewald Theresa Thor Andrea Odersky Marc Schulte Hedwig E. Deubzer Lukas Heukamp Angelika Eggert Alexander Schramm Johannes H. Schulte Annette Künkele

Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-70% survival. Secondary chemotherapy resistance contributes to treatment failure, where TP53 pathway dysfunction plays a key role. MDM2 interaction with TP53 leads to its degradation. Reactivating TP53 functionality using small-molecule inhibitors, such as RITA, to disrupt TP53-MDM2 binding may h...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید